Review article: the reversibility of cirrhosis

被引:106
作者
Sohrabpour, A. A. [1 ]
Mohamadnejad, M. [1 ]
Malekzadeh, R. [1 ]
机构
[1] Univ Tehran Med Sci, Digest Dis Res Ctr, Shariati Hosp, Tehran, Iran
关键词
CHRONIC HEPATITIS-B; FATTY LIVER-DISEASE; STEM-CELL TRANSPLANTATION; SUSTAINED VIROLOGICAL RESPONSE; AUTOIMMUNE HEPATITIS; NONALCOHOLIC STEATOHEPATITIS; TRANSIENT ELASTOGRAPHY; ADEFOVIR DIPIVOXIL; E-ANTIGEN; INFLAMMATORY INFILTRATE;
D O I
10.1111/apt.12044
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Background Cirrhosis is the end result of many types of chronic liver diseases. Recent developments in the understanding of the process of hepatic fibrogenesis have revealed that the process is a dynamic one and a capacity for recovery from any degree of fibrosis including those associated with cirrhosis is plausible. Aim To review current evidence of histopathological reversibility following drug therapy of more common aetiologies of cirrhosis. Methods A PubMed search was performed and the evidence for histopathological regression of advanced fibrosis/cirrhosis following drug therapy was reviewed as of the end of February 2012. Results There is abundant clinical evidence in support of the idea of the reversibility of cirrhosis in patients with different aetiologies of advanced hepatic disease including viral, autoimmune and metabolic/infiltrative liver disease. Conclusions The concept of cirrhosis has changed from being a form of static and irreversible entity to a dynamic and reversible diseases stage. Novel therapeutic strategies are under investigation to target specific steps in the process of fibrogenesis with the aim of reversing advanced fibrosis/cirrhosis.
引用
收藏
页码:824 / 832
页数:9
相关论文
共 102 条
[1]
Abedian S, 2011, MIDDLE E J DIG DIS, V1, P56
[2]
[Anonymous], 2011, J HEPATOL, V55, P245
[3]
[Anonymous], 2011, HISTOLOGIC IMPROVEME
[4]
Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment [J].
Barry-Hamilton, Vivian ;
Spangler, Rhyannon ;
Marshall, Derek ;
McCauley, Scott ;
Rodriguez, Hector M. ;
Oyasu, Miho ;
Mikels, Amanda ;
Vaysberg, Maria ;
Ghermazien, Haben ;
Wai, Carol ;
Garcia, Carlos A. ;
Velayo, Arleene C. ;
Jorgensen, Brett ;
Biermann, Donna ;
Tsai, Daniel ;
Green, Jennifer ;
Zaffryar-Eilot, Shelly ;
Holzer, Alison ;
Ogg, Scott ;
Thai, Dung ;
Neufeld, Gera ;
Van Vlasselaer, Peter ;
Smith, Victoria .
NATURE MEDICINE, 2010, 16 (09) :1009-U107
[5]
Liver fibrosis [J].
Bataller, R ;
Brenner, DA .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (02) :209-218
[6]
Genetic polymorphisms and the progression of liver fibrosis: A critical appraisal [J].
Bataller, R ;
North, KE ;
Brenner, DA .
HEPATOLOGY, 2003, 37 (03) :493-503
[7]
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis [J].
Belfort, Renata ;
Harrison, Stephen A. ;
Brown, Kenneth ;
Darland, Celia ;
Finch, Joan ;
Hardies, Jean ;
Balas, Bogdan ;
Gastaldelli, Amalia ;
Tio, Fermin ;
Pulcini, Joseph ;
Berria, Rachele ;
Ma, Jennie Z. ;
Dwivedi, Sunil ;
Havranek, Russell ;
Fincke, Chris ;
DeFronzo, Ralph ;
Bannayan, George A. ;
Schenker, Steven ;
Cusi, Kenneth .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (22) :2297-2307
[8]
NERVES AND PERISINUSOIDAL CELLS IN HUMAN-LIVER [J].
BIOULACSAGE, P ;
LAFON, ME ;
SARIC, J ;
BALABAUD, C .
JOURNAL OF HEPATOLOGY, 1990, 10 (01) :105-112
[9]
Assessing fibrosis without a liver biopsy: Are we there yet? [J].
Bissell, DM .
GASTROENTEROLOGY, 2004, 127 (06) :1847-1849
[10]
The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C [J].
Bonacchi, A ;
Petrai, I ;
DeFranco, RMS ;
Lazzeri, E ;
Annunziato, F ;
Efsen, E ;
Cosmi, L ;
Romagnani, P ;
Milani, S ;
Failli, P ;
Batignani, G ;
Liotta, F ;
Laffi, G ;
Pinzani, M ;
Gentilini, P ;
Marra, F .
GASTROENTEROLOGY, 2003, 125 (04) :1060-1076